We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction (MBO—IR)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by Tianjin Medical University Cancer Institute and Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01073514
First Posted: February 23, 2010
Last Update Posted: December 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital
February 21, 2010
February 23, 2010
December 22, 2015
December 2009
November 2016   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01073514 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction
Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction
To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.
We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
bile,blood and urine specimen
Probability Sample
Malignant obstructive jaundice (MBO)
Malignant Biliary Obstruction
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
300
December 2016
November 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria:

  • Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01073514
TMU-CIH-IR-001
ChiCTR-ONC-00000752 ( Registry Identifier: Chinese Clinical Trial Register(http://www.chictr.org) )
Yes
Not Provided
Not Provided
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Not Provided
Principal Investigator: YU HAI PENG, MD Tianjin Medical University Cancer Institute and Hospital
Study Chair: GUO ZHI, Professor Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
February 2010